ALIVUS

Alivus Life share price & financials

Price
₹1,070.3
Market cap
₹16.3k Cr
Sector
Healthcare
Calls analysed
8
Latest concall · Q1 FY27 · call held 31 Jul 2026

Alivus Life Q1 FY27

Revenue from Operations ₹640 cr +6%EBITDA ₹234 cr +29%EBITDA Margin 36.6% PAT ₹160 cr

What went well

  • Revenue from operations grew 6.4% YoY to INR640 crores, driven by strong non-GPL performance.
  • Gross margins expanded by 510 bps YoY to 60.2%, supported by favorable product mix and new launches.
  • EBITDA margin improved by 650 bps YoY to 36.6%, reaching INR234 crores, reflecting operational efficiencies and forex gains.

What to watch

  • GPL business saw a significant decline of 52.6% year-on-year due to inventory rationalization.
  • The war situation has made management cautious about raw material prices and their impact on margins.
Read the full call →

What Alivus Life does

Alivus Life Sciences (formerly Glenmark Life Sciences, spun out of Glenmark Pharmaceuticals and now majority-owned by Nirma Limited) manufactures active pharmaceutical ingredients (APIs) sold to generic-drug makers worldwide, alongside a Contract Development and Manufacturing Organisation (CDMO) business that develops and manufactures APIs for third-party pharma customers. It runs four API manufacturing plants in Gujarat and Maharashtra and supplies molecules across therapy areas such as cardiovascular, CNS, diabetes, oncology, urology and pain management to customers in regulated and emerging markets. A fifth, greenfield plant is under construction at Solapur, Maharashtra, and the company maintains an in-house R&D and regulatory-filing base that underpins its DMF/CEP registrations across major global markets.

Segments

  • Generic API
  • CDMO (Contract Development & Manufacturing Organisation)
Manufacturing facilities
4 (Ankleshwar & Dahej in Gujarat; Mohol & Kurkumbh in Maharashtra), plus a greenfield plant under construction at Solapur
Total installed reactor capacity
1,424 KL
DMF/CEP filings (cumulative)
611 filings across US, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia
Customer base
~900 customers globally (FY26); 700+ customers across 75+ countries as of FY25
Employees
2,203, including 163 women employees
High-potency API (HPAPI) pipeline
28 products in development grid; 12 validated, 7 in advanced stages
Founded 2011Headquarters Mumbai, Maharashtra (corporate office); Solapur, Maharashtra (registered office)Employees 2,203 (2025-03-31) Company website

Guidance record · Q1 FY27

what the last two calls moved 21 tracked 3 delivered 5 missed 13 open
  • FY25 Gross Margin delivered said Q2 FY25 Promised: 52-55% Q1 FY27: Promise concluded in a prior period.
  • FY25 Revenue Growth missed said Q2 FY25 Promised: high single digit (revised down from mid-teens) Q1 FY27: Promise concluded in a prior period.
  • Solapur Operational Start delayed said Q2 FY25 Promised: End of Q3 FY26 Q1 FY27: Timeline delayed again, from Q2 FY27 to 'early Q3 FY27'. Management cites a calibrated approach to avoid under-absorption.

All 21 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 6.3%, net profit up 31.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue507 642 650 602 588 +16%673 +5%689 +6%640 +6%
EBITDA134 190 198 172 179 +34%231 +22%215 +9%212 +23%
Net profit95 137 142 122 130 +37%150 +9%163 +15%160 +31%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +45.3% 1Y

₹1.0k₹1.2k₹1.4kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q3 FY26 — 22 Jan 2026Q4 FY26 — 15 May 2026Q1 FY27 — 31 Jul 2026

1Y: ₹954.65 on 10 Sept 2025 → ₹1,386.8. High ₹1,443.7 (1 Sept 2026), low ₹860.05 (8 Dec 2025).

How the price took the results

close before → close after

Q1 FY27
+5.9%
31 Jul
Q4 FY26
−1.8%
15 May
Q3 FY26
+0.0%
22 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 5.7% a year over 3 years, FY23 to FY26. Operating margin widened to 31.2%.

Year endingFY23FY24FY25FY26
Revenue₹2.2k Cr₹2.3k Cr₹2.4k Cr₹2.6k Cr
Operating profit₹642 Cr₹674 Cr₹681 Cr₹797 Cr
Operating margin29.7%29.5%28.5%31.2%
Interest₹0 Cr₹0 Cr₹1 Cr₹4 Cr
Depreciation₹43 Cr₹54 Cr₹60 Cr₹75 Cr
Net profit₹467 Cr₹471 Cr₹485 Cr₹565 Cr
Net margin21.6%20.6%20.3%22.1%
Cash from operations₹306 Cr₹414 Cr₹392 Cr₹565 Cr
Free cash flow₹143 Cr₹285 Cr₹226 Cr₹259 Cr
ROCE30.0%28.0%25.0%24.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹2 Cr₹25 Cr₹25 Cr₹25 Cr₹25 Cr₹25 Cr
Reserves₹751 Cr₹2.0k Cr₹2.1k Cr₹2.3k Cr₹3.0k Cr₹3.3k Cr
Borrowings₹0 Cr₹3 Cr₹19 Cr₹17 Cr₹60 Cr₹57 Cr
Other liabilities₹1.2k Cr₹414 Cr₹545 Cr₹501 Cr₹563 Cr₹594 Cr
Total liabilities₹2.0k Cr₹2.5k Cr₹2.7k Cr₹2.9k Cr₹3.6k Cr₹4.0k Cr
Fixed assets₹573 Cr₹595 Cr₹781 Cr₹805 Cr₹969 Cr₹1.0k Cr
Capital work in progress₹14 Cr₹92 Cr₹62 Cr₹106 Cr₹173 Cr₹284 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹634 Cr₹780 Cr
Other assets₹1.4k Cr₹1.8k Cr₹1.9k Cr₹1.9k Cr₹1.9k Cr₹1.9k Cr
Total assets₹2.0k Cr₹2.5k Cr₹2.7k Cr₹2.9k Cr₹3.6k Cr₹4.0k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs added +1.56 pp while FIIs trimmed −0.88 pp. The shareholder count shrank 9% to 1,25,559.

Promoters
74.9%
FIIs
5.5%
DIIs
7.2%
Public
12.4%

Since Jun 2025

  • DIIs +1.56 pp
  • FIIs −0.88 pp
  • Public −0.61 pp

How it drifted, 12 quarters

Over this window promoters fell from 82.8% to 74.9% — −8.0 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 82.8%, FIIs 4.4%, DIIs 0.6%, Public 12.1%.Dec '23: Promoters 82.8%, FIIs 4.6%, DIIs 0.7%, Public 11.8%.Mar '24: Promoters 82.8%, FIIs 5.0%, DIIs 1.4%, Public 10.7%.Jun '24: Promoters 82.8%, FIIs 4.8%, DIIs 1.6%, Public 10.8%.Sep '24: Promoters 75.0%, FIIs 7.8%, DIIs 4.2%, Public 13.0%.Dec '24: Promoters 75.0%, FIIs 6.7%, DIIs 4.9%, Public 13.4%.Mar '25: Promoters 75.0%, FIIs 6.6%, DIIs 5.2%, Public 13.3%.Jun '25: Promoters 74.9%, FIIs 6.4%, DIIs 5.6%, Public 13.0%.Sep '25: Promoters 74.9%, FIIs 6.8%, DIIs 5.5%, Public 12.8%.Dec '25: Promoters 74.9%, FIIs 5.1%, DIIs 7.1%, Public 12.9%.Mar '26: Promoters 74.9%, FIIs 5.3%, DIIs 7.3%, Public 12.6%.Jun '26: Promoters 74.9%, FIIs 5.5%, DIIs 7.2%, Public 12.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Alivus Life above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Nirma Limited 74.87%unchanged
Quant Mutual Fund - Quant Small Cap Fund Mutual fund2.51%unchanged
Government Pension Fund Global Sovereign2.40%+0.06 pp
Massachusetts Institute Of Technology Endowment1.23%unchanged
Trona Railway Company LLC, USA 0.00%unchanged
Searles Valley Minerals Inc., USA 0.00%unchanged
Karnavati Holdings Inc., USA 0.00%unchanged
Searles Valley Minerals Europe, France 0.00%unchanged
Searles Domestic Water Company LLC, USA 0.00%unchanged
ICICI Prudential Pharma Healthcare And Diaganostic Mutual fund—off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Expensive

To justify its price of ₹1387, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~6%. At that growth it is worth ₹689 — downside of 50%.

Growth the price implies
19.7% a year
for 7 years, fading to 4%
It has actually compounded at
6.6% a year
net profit, FY23–FY26 · EPS 6.5%
The gap
0.1 pp
-50% downside if it only repeats history
Price today ₹1,386.8 Value at the reference growth ₹689

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Alivus Life

Guides on how to read this kind of business and the numbers that matter.